THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Story continues below

Item 5.02 of the Original Report is hereby amended to add the following information:

(e) On January2, 2019, the Company and Ms.Gala entered into a consulting agreement to facilitate the transition of activities following Ms.Gala’s departure, to which certain outstanding equity awards will continue to vest during these transition activities, and a copy of which is included in this Amended Report as Exhibit99.1.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Theravance Biopharma, Inc. Exhibit
EX-99.1 2 a19-1051_1ex99d1.htm EX-99.1 Exhibit 99.1   CONSULTING AGREEMENT   Effective January 2,…
To view the full exhibit click here

About THERAVANCE BIOPHARMA,INC. (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

An ad to help with our costs